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We have established a highly sensitive and quantitative reverse transcriptase–polymerase chain reaction (RT–PCR) method to
detect axillary lymph node metastases of breast cancer. Amplifying cytokeratin 19 (CK19) mRNA transcripts using real-time TaqMan
PCR made it possible to quantify axillary metastatic burden. Metastases in 358 axillary lymph nodes obtained from 23 breast cancers
of 22 patients were investigated by conventional haematoxylin and eosin (H&E) staining, immunohistochemical staining and
quantitative RT–PCR assay. The detection rates of axillary lymph node metastasis using H&E staining, immunohistochemistry and
RT–PCR assay were 4.5, 5.9 and 13.1%, respectively. RT–PCR assay was the most sensitive of these three methods for detecting
lymph node metastases. Cytokeratin 19 mRNA expression values of both histologically and immunohistochemically positive lymph
nodes were significantly higher than the values for lymph nodes judged to be negative by both histological and immunohistochemical
methods (Po0.0001), and those of histologically negative, but immunohistochemically positive lymph nodes were significantly higher
than the values for lymph nodes judged to be negative by both histological and immunohistochemical methods (Po0.0001).
Furthermore, metastatic rates of sentinel nodes were higher than the rates of nonsentinel lymph nodes as measured by all three
methods. These results indicate that quantitative RT–PCR assay is a sensitive and reliable method for detecting lymph node
metastasis. Furthermore, quantification of metastases in sentinel lymph nodes by quantitative RT–PCR assay may be useful to assess
the entire axillary burden of breast cancer patients.
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Axillary lymph node status is the most powerful predictor of
patient prognosis in cases of breast cancer (Fisher et al, 1983), and
patients without axillary lymph node metastases have a better
prognosis. However, 15–30% of node-negative patients suffer
from a recurrence within 5 years (Fisher et al, 1983; Giuliano et al,
1995; Saimura et al, 1999). Previous studies have reported that
routine haematoxylin and eosin (H&E) staining analysis of axillary
lymph nodes may miss micrometastases in the range of 9–25% of
patients that can be readily detected by serial sectioning
(International (Ludwig) Breast Cancer Study Group, 1990;
Mascarel et al, 1992; Nasser et al, 1993) and immunohistochemical
staining (Mascarel et al, 1992; Hainsworth et al, 1993; Nasser et al,
1993; Cote et al, 1999). However, these methods are too
cumbersome, too time-consuming, and too costly to be used in
routine examinations (Lockett et al, 1998).
Several reports have indicated that the detection of micro-
metastases using reverse transcriptase–polymerase chain reaction
(RT–PCR) assay may be clinically important (Noguchi et al, 1994,
1996; Schoenheld et al, 1994; Mori et al, 1995, 1998; Masuda et al,
2000; Manzotti et al, 2001). Moreover, screening for metastatic
disease in axillary lymph nodes by RT–PCR amplification has
been shown to be more sensitive and cost effective than serial
sectioning and immunohistochemical staining (Lockett et al,
1998). However, there are also reports on the limitations of this
method (Zippelius et al, 1997; Bostick et al, 1998a,b; Ko et al,
2000). The major limitation is related to the specificity in the
detection of metastatic cancer cells. The target genes can even be
expressed in blood samples from healthy humans and noncancer-
ous patients. This is partially attributable to the nonquantitative-
ness of the conventional RT–PCR assay, in which PCR products
are visualised by staining with ethidium bromide or autoradio-
grams, and for which detection depends on the number of
amplification cycles and the design of the primers. The expression
of the target gene has been defined only as positive or negative and
not quantified in conventional RT–PCR assay. The detection of
lymph node metastases would be more reliable by quantitative
evaluation of PCR products, because faint signals from normal
lymphocytes could be distinguished from cancer-related signals by
the difference in signal intensities.
Recently, a real-time detection and quantitative PCR assay has
been developed, which is based on the TaqMan methodology
(Gibson et al, 1996). Its advantage is the specific detection of rare
events. The sensitivity of the assay allows for the detection of 10–
100pg of RNA. This method uses the 50–30 exonuclease activity of
Taq polymerase to cleave a dual-labelled probe annealed to a target
sequence during the extension phase of PCR. It is highly
reproducible and quantitative, and it eliminates the major risks
of contamination encountered with other types of detection
(nested PCR and competitive PCR). In addition, no post-PCR
manipulations are required with this method, and quantification
and calculation of the results are all automated. Received 4 February 2003; revised 26 June 2003; accepted 8 July 2003
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yCurrently, many investigators reported sentinel lymph node
biopsy for the diagnosis of axillary lymph node metastases from
breast cancer (Giuliano et al, 1994; Albertini et al, 1996; Veronesi
et al, 1997; Krag et al, 1998). The sentinel lymph node is the first
lymph node to receive drainage from the primary tumours in early
stage cancers (Morton et al, 1992). Therefore, a tumour-free
sentinel lymph node implies the absence of lymph node metastases
in the entire lymphatic basin. This sentinel node concept had been
previously confirmed by H&E examinations, immunohistochem-
ical study and nonquantitative RT–PCR assays (Giuliano et al,
1994; Albertini et al, 1996; Veronesi et al, 1997; Krag et al, 1998;
Kataoka et al, 2000; Manzotti et al, 2001; Branagan et al, 2002;
Ishida et al, 2002).
The purpose of this study was to develop a quantitative RT–
PCR assay based on real-time TaqMan PCR for detecting and
quantifying metastases in axillary lymph nodes of breast cancer,
and also to study the feasibility of the sentinel lymph node biopsy
technique by using quantitative RT–PCR assay.
MATERIALS AND METHODS
Patients and treatment (sentinel lymph node biopsy)
A total of 22 Twenty-two women with a case of Tis (carcinoma in
situ), clinical stage I or II primary breast cancers (one with
bilateral breast cancers), were treated by the Department of
Surgery , Kanazawa University Hospital between June 1999 and
September 2000. Two cases had already undergone excisional
biopsy at the other hospital. After receiving informed consent, the
patients were scheduled to undergo preoperative lymphoscinti-
graphy and sentinel lymph node biopsy. The protocol was
approved by the Local Ethics Committee at the Kanazawa
University School of Medicine. Lymphatic mapping and sentinel
lymph node biopsy were performed as described previously
(Tsugawa et al, 2000). Then the primary lesion was removed.
Finally, a complete dissection (level I–II) of the axillary lymph
nodes was performed conventionally. The operative methods
included modified radical mastectomy in 16 patients (one received
bilateral mastectomy) and wide excision with axillary lymph node
dissection in six patients. The clinicopathological findings were
classified according to the Histologic Classification of Breast
Cancer proposed by the Japanese Breast Cancer Society (The
Japanese Breast Cancer Society, 2000), which are modified
histological types from the World Health Organization.
Clinical samples
Lymph node samples After sentinel lymph node biopsy, each
lymph node was entirely cut into 2mm thick slices. Each node was
cut into two to 10 slices. For each sliced node, even number of
these slices was examined by routine H&E and immunohisto-
chemical staining as permanent sections. The odd number of these
slices was subjected to RT–PCR assay.
After axillary lymph node dissection, the lymph nodes were
macroscopically isolated from the specimens. Each node was cut
into halves. One half being examined by H&E and immunochem-
ical staining was cut into more 2mm thick slices (one to four
sections); and the remaining half being subjected to RNA
extraction (Figure 1).
Cancer cell line and normal control The human mammary cancer
cell line MCF-7 was used as a positive control for cancer cell
detection by quantitative RT–PCR assay. The cell line was
maintained in RPMI 1640 (Nissui Pharma. Co., Ltd, Tokyo, Japan)
supplemented with 10% heated, inactivated fetal bovine serum
(Life Technologies, Inc., Gaithersburg, MD, USA) at 371C and
5% CO2.
As a negative control, 24 normal lymph nodes from non-
cancerous patients (chronic cholecystitis and haemorrhagic gastric
ulcer) were obtained at the time of surgery (cholecystectomy or
gastrectomy) under the informed consents and studied in order to
determine the cutoff value of quantitative RT–PCR assay.
Total RNA extraction and first-strand cDNA synthesis
The acid guanidinium thiocyanate–phenol–chloroform extraction
procedure was used for the extraction of total RNA from MCF-7,
primary carcinoma tissue, corresponding normal breast tissue,
dissected lymph nodes, peripheral mononuclear cells from healthy
volunteer and normal lymph nodes (Chomczynski and Sacchi,
1987). The quantity and quality of the extracted RNA was
confirmed by absorption measurement at 260 and 280nm using
the spectrophotometer (U-2000A, HITACHI, Tokyo, Japan). The
prepared RNA (10mg) was mixed with 500pmol of the oligo dT
primer for 15min at 681C. After heat-denaturing, each sample was
quickly chilled on ice for 5min. The RNA sample was reverse-
transcribed at 421C for 60min into first-strand cDNA in reverse-
transcription solution (400U of Moloney murine leukaemia virus
reverse transcriptase (Life Technologies, Inc.), 50mM Tris-HCl (pH
8.3), 75mM KCl, 3mM MgCl2, 0.01 M DTT, 0.5mM each dNTP, and
16U of RNasin (Promega, Madison, WI, USA) with a total volume
of 100ml.
Quantitative PCR assay
We focused on cytokeratin 19 (CK19) as RNA targets to detect
cancer cells in the axillary lymph node. Optimal primers and
probes were selected using Software Primer Express Ver.1.7
provided by PE Applied Biosystems (Foster, CA, USA). The
TaqMan glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
Control Reagent (PE Applied Biosystems) was used for PCR of
GAPDH mRNA as an internal reference. The sequences of primers
and internal probes for CK19 and GAPDH mRNA are given in
Table 1.
In order to prevent amplification from the processed pseudo-
gene (CK19a and CK19b) (Ruud et al, 1999), primers and internal
probes were designed to maximise the sequence difference between
CK19 and its pseudogenes. The internal probe for CK19 was
labelled with a reporter dye (FAM: 6-carboxy-fluorescein) at the 50-
end and a quencher dye (TAMRA: 6-carboxy-tetramethyl-rhoda-
mine) at the 30-end.
The PCR solution (50ml) was composed of 1ml of cDNA solution
corresponding to 100ng of total RNA, 200nM of each of the
forward and reverse primer, 100nM of internal probe and TaqMan
Universal Master Mix (PE Applied Biosystems), which contained
Sentinel node
Nonsentinel node
H&E
IHC
H&E
IHC
2 mm
2 mm
RT -  PCR
assay
RT -  PCR
assay
Figure 1 Section of the lymph node samples.
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yAmpli-Taq Gold DNA polymerase, a reaction buffer, dNTP, dUTP
and AmpErase uracil-N-glycosylase. PCR was carried out for 2min
at 501C, 10min at 951C followed by 40 cycles of 15s at 951C and
1min at 601C using the ABI 7700 Prism Sequence Detector (PE
Applied Biosystems). PCR amplification of GAPDH mRNA was
conducted according to the manufacturer’s instructions for the
TaqMan GAPDH Control Reagent.
The quantification of mRNA levels of the target gene was made
using real-time fluorescence detection ‘TaqMan TM’ technology.
Reactions were characterised at the point during cycling when
amplification of the PCR product is first detected, rather than
according to the amount of PCR product accumulated after a fixed
number of cycles. The larger the starting quantity of the target
molecule, the earlier a significant increase in fluorescence was
observed. The parameter threshold cycle (Ct) is defined as the
fractional cycle number at which the fluorescence generated by
cleavage of the probe passes a fixed threshold above baseline. The
target message in unknown samples is quantified by measuring Ct
and by using a standard curve to determine the starting target
message quantity. Standard curves for target genes were generated
using serial dilutions (10
 1–10
 5) of RNA derived from breast
cancer cell line (MCF-7 cells) in each assay.
Both the precise amount and quality of total RNA added to each
reaction mix (based on absorbance) are difficult to assess.
Therefore, we also quantified transcripts of the GAPDH gene as
an internal reference according to a quantitative PCR assay, and
each sample was normalised on the basis of its GAPDH content.
Lymph node samples were considered eligible for study when the
GAPDH Ct value was p35, that is, suggesting an appropriate
starting amount and quality of total RNA.
The amounts of target mRNA in samples were calculated relative
to those in MCF-7 and standardised according to those of GAPDH
mRNA. The quantification value of CK19 mRNA was described as
an amount relative to the MCF-7.
Immunohistochemistry
To confirm the quantitative RT–PCR analysis histologically, an
immunohistochemical examination was performed for all the
lymph nodes. Anti-cytokeratin 19 antibodies (DAKO, Glostrup,
Denmark) were used for detecting metastatic cancer cells in the
lymph nodes. Immunohistochemistry was carried out by using the
Envisionþ peroxidase kit (DAKO). Lymph nodes were scored
positive when the cells stained clearly CK19 and had the
morphological characteristics of malignant cells.
Statistical analysis
Categorical variables were compared using the w
2 test, employing
the Yates correction when necessary. Continuous variables were
compared using the Mann–Whitney U-test. All P-values were two-
sided. A P-value of less than 0.05 indicated a significant difference.
RESULTS
Study I: Quantification of metastases in axillary lymph
nodes
Characteristics of patients and tumours A total of 358 axillary
lymph nodes were obtained from 23 breast cancers of 22 patients.
The general characteristics of the patients with breast cancer are
presented in Table 2. The average age of the patients was 53 years
(range 30–77). In all, 10 patients had clinically negative nodes
(N0) (one with bilateral N0), and 12 had positive nodes (N1).
Haematoxylin and eosin staining and immunohistochemistry A-
mong 358 lymph nodes from 23 tumours, 16 nodes (4.5%) in six
cases had tumour involvement as indicated by staining of H&E. All
the histologically positive lymph nodes indicated by H&E also had
CK19-expressing tumour cells indicated by immunohistochemical
methods. Moreover, five of the histologically negative lymph nodes
indicated by H&E had occult metastases indicated only by
immunohistochemical methods (Figure 2). In total, 21 nodes
Figure 2 Immunohistochestochemical detection of cancer cells in the
axillary lymph node. Photomicrograph of CK19-positive cancer cells in
lymph node (magnification 400).
Table 1 Primer and probe sequences for quantitative RT–PCR
Target gene Sequence 50–30
CK19 Forward primer GAAGAACCATGAGGAGGAAATCA
Reverse primer ACCTCATATTGGCTTCGCATGT
Probe (FAM)-CGGGCACCGATCTCGCCAAG-(TAMRA)
GAPDH Forward primer GAAGGTGAAGGTCGGAGTC
Reverse primer GAAGATGGTGATGGGATTTC
Probe (JOE)-CAAGCTTCCCGTTCTCAGCC-(TAMRA)
CK19¼cytokeratin 19; GAPDH¼glyceraldehyde-3-phosphate dehydrogenase;
FAM¼6-carboxy-fluorescein, reporter dye; JOE¼2,7-dimethoxy-4,5-dichloro-6-
carboxy-fluorescein), reporter dye; TAMRA¼6-carboxy-tetramethyl-rhodamine,
quencher dye.
Table 2 Clinicopathological characteristics of patients with breast cancer
Age (mean) (years) 30–77 (55)
Menopausal status
Pre 9
Post 13
Pathological stage (TNM)
01
I7
IIA/B 14
IIIA 1
Histological type of tumour
Invasive ductal cancer 21
Noninvasive ductal cancer 2
Lymphatic invasion
Positive 13
Negative 8
Unknown
a 2
Axillary involvement (histology)
Present 6
Absent 17
Operation methods
Modified radical mastectomy 17
Breast-conserving surgery 6
aAfter excisional biopsy state.
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immunohistochemistry.
Sensitivity of quantitative RT–PCR assay In order to estimate the
sensitivity of RT–PCR assays, serial dilution experiments were
carried out. A volume of 100ng of RNA derived from MCF-7 was
diluted from 10
 1 to 10
 6 and subjected to RT–PCR assay. In
Figure 3A, amplification plots for the sample containing serial
dilutions of RNA derived from MCF-7 cells are overlaid. The
standard curve was constructed from plots for the calculated Ct
values of each reaction (Figure 3B). Figure 3B shows that it is
possible to quantify CK19 mRNA expression in spans of five logs.
CK19 transcripts were detected up to 10
 4 corresponding to
10
 6mg of MCF-7 total RNA. Cytokeratin 19 assays of MCF-7 cell-
derived genomic DNA results do not arise from amplification of
the processed pseudogenes. The same results were obtained for
GAPDH mRNA (data not shown).
Quantification of CK19 mRNA expression in lymph nodes Among
358 lymph nodes, 91 (25.4%) showed CK19 mRNA expression
(2.8 10
 4–1.7 10
2) (Figure 4). All the 16 histologically positive
lymph nodes showed CK19 mRNA expression. Four nodes showed
CK19 mRNA expression among five nodes, in which lymph node
metastasis was detected only by immunohistochemistry. The
expression values of both histologically and immunohistochemi-
cally positive lymph nodes ranged from 2.5 10
 3 to 1.7 10
2,
which were significantly higher than the values for either
histologically or immunohistochemically determined negative
lymph nodes, for which values ranged from 0 to 1.4 10
(Po0.0001). Furthermore, the expression values of histologically
negative, but immunohistochemically positive lymph nodes ranged
from 0 to 5.3 10
 1, which were significantly higher than both the
values for either histologically or immunohistochemically deter-
mined negative nodes (Po0.0001).
In order to exclude false positives, we used as the cutoff value
the average mRNA valueþ2s.d. of CK19 mRNA expression in
normal lymph nodes from noncancerous patients (3.3 10
 3 for
CK19). Values above or equal to this cutoff value of CK19 mRNA
were defined as CK19 mRNA positive. The results of the
comparison between histological examination and quantitative
RT–PCR method using a cutoff value are shown in Table 3. Using
the cutoff value method, 31 (9.1%) of histologically negative
lymph nodes were determined to be CK19 positive (Table 3).
Moreover, three out of four of the nodes that were determined
to be histologically negative, but immunohistochemically positive,
were determined to be CK19 mRNA positive. Thus, CK19
mRNA positive nodes were strongly expected to possess cancer
cells in the lymph nodes. Therefore, the cutoff value of CK19
mRNA expression was used as described above in the subsequent
study.
In the detection of breast cancer metastases in axillary lymph
nodes, immunohistochemistry and the RT–PCR method were
more sensitive than the usual H&E methods in terms of their
ability to detect axillary lymph node metastasis (Table 4).
Furthermore, metastatic rates of axillary lymph nodes using
immunohistochemistry and the RT–PCR method were higher
than the rates observed when using the H&E methods (Table 5).
Study II: Metastasis detection in sentinel lymph nodes
Identification of sentinel lymph node Intraoperative sentinel
lymph node identification of axillary lesions was successful in all
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Figure 3 Amplification of CK19 mRNA by quantitative PCR assay. (A)
Amplification plots of CK19 mRNA for serial dilution of MCF-7 total RNA.
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Figure 4 Relative expression of CK19 mRNA.
Table 3 Relation between histological examination and quantitative
RT–PCR method in the detection of metastasis in 358 axillary lymph nodes
Histological analysis
RT–PCR analysis Negative (%) Positive (%)
(CK19) (n¼342) (n¼16)
Negative 311 (90.9) 0
Positive 31 (9.1) 16 (100)
CK19¼cytokeratin 19.
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four (mean 2.0) lymph nodes. In total, 45 sentinel lymph nodes
were identified and 358 lymph nodes, including sentinel nodes,
were dissected. The axillary sentinel lymph nodes contained cancer
metastases in six (26%) of 23 breasts in 22 patients by H&E
staining. For two of the patients, only the sentinel lymph nodes
were metastatic nodes, whereas the remaining four breasts also
had metastasis in other axillary nodes. The evaluation of
metastasis by conventional H&E staining revealed that this sentinel
node biopsy technique is 100% in terms of both diagnostic
accuracy and sensitivity.
Quantification of CK19 mRNA expression of sentinel lymph nodes
and nonsentinel lymph nodes No significant differences of CK19
mRNA expression values were found between sentinel lymph
nodes and nonsentinel lymph nodes. Among 39 of the histologi-
cally negative sentinel lymph nodes, CK19 mRNA positive nodes
were five (12.8%). Two of the five nodes had immunohistochemi-
cally CK19 positive metastases. However, two nodes showing
immunohistochemically CK19 positive cancer cluster did not show
CK19 mRNA signal by quantitative RT–PCR assay among
histologically negative sentinel lymph nodes. In total, six of the
tumour-involved sentinel lymph nodes were detected by H&E
staining and seven more tumour-involved sentinel lymph nodes
were detected using either immunohistochemistry or RT–PCR
assay.
The metastatic rate for the sentinel lymph nodes was
significantly higher than that of the nonsentinel nodes, irrespective
of which of the three methods was used. The metastatic rates of the
sentinel and nonsentinel lymph nodes as indicated by the RT–PCR
method were higher than those resulting from H&E and
immunohistochemical staining (Table 6).
DISCUSSION
In this study, we have established a highly sensitive and
quantitative RT–PCR assay to detect axillary lymph node
metastases of breast cancer. We also proved the reliability of our
sentinel lymph node biopsy technique by using this RT–PCR
assay. Furthermore, we could assess the quantity of metastatic
cancer cells in the axillary lymph nodes.
Usually, lymph node metastasis is assessed only in one section
from the centre of the lymph node using H&E or immunohisto-
chemical staining. These examination methods carry the risk of
ignoring the metastatic foci if they are present at the periphery of
the node. The RT–PCR assay offers the advantage of metastasis
detection in the whole node as compared to H&E and immuno-
histochemical staining.
Recently, RT–PCR assays with tumour-specific gene markers
such as CK19, CEA, MUC1, PIP, Mapsin and mammaglobin B
have been widely used to detect occult metastasis in cancer
patients (Noguchi et al, 1994, 1996; Schoenheld et al, 1994;
Mori et al, 1995, 1998; Kataoka et al, 2000; Masuda et al, 2000;
Manzotti et al, 2001; Mitas et al, 2001). To date, however, no
marker that is expressed in all breast cancer tissues, but not
in normal lymph node has been available, partly because of
the heterogeneity of marker gene expression in cancer cells.
Therefore, multimarker analysis will probably be necessary for
the precise and accurate examination of lymph node metastasis
(Manzotti et al, 2001; Mitas et al, 2001). On the other hand,
some evidence suggests that false positives may arise due to several
factors, including illegitimate CK19 mRNA expression in lympho-
cytes, the presence of noncancerous epithelial cells in lymph
nodes and the use of inappropriate primer modification and
too many PCR amplification cycles (Bostic et al, 1998b). In the
present study, we designed our original CK19 primers and probes
to minimise amplifying illegitimate mRNA. Using the ABI 7700
Prism Sequence Detector (PE Applied Biosystems) and our
original primers and probes, we could quantify the target gene,
and minimise amplifying inappropriate genes. We also amplified
and quantified CEA and mammaglobin B mRNA as multimarkers
for metastasis detection (data not shown). The detection of
metastasis by mammaglobin B resulted in low sensitivity. The
signal intensity of CEA mRNA from normal lymph nodes was
extremely high. Therefore, we selected CK19 as the target gene in
this study.
It is unclear whether the signal showed by RT–PCR assay
reflects cancer-specific signals. It was not possible to show the
RT–PCR positive cancer cells histologically. In the present study,
we extracted RNA from one entire half of a lymph node, and the
remaining half was examined using H&E or immunohistochemical
staining. Histologically positive lymph nodes showed significantly
higher CK19 mRNA values, while histologically negative lymph
nodes showed significantly lower rates. Surprisingly, most of the
histologically negative, but immunohistochemically positive,
lymph nodes showed high CK19 mRNA value. These results
indicated that cancer detection using quantitative RT–PCR assay
is reliable. Although the result of immunohistochemistry and RT–
PCR was not necessarily in agreement in our study, this is
probably due to the fact that the same portions of the lymph node
samples were not examined by both methods. The rate of lymph
node metastatic detection goes up by increasing the volume of the
Table 4 Detection of metastasis by H&E, IHC and the RT–PCR method
on 358 axillary lymph nodes
Detection procedure Metastatic ratio (%)
H&E   4.5 
IHC 5.9 
RT-PCR 13.1
* *
*
H&E¼haematoxylin and eosin; IHC¼immunohistochemistry *Po0.0001,
**Po0.005.
Table 5 Axillary lymph node metastasis detection by histological
examination (HE), immunohistochemistry (IHC) and quantitative RT–
PCR method in 22 breast cancer patients
Axillary lymph node metastasis
Detection procedure Positive Negative Metastatic rate (%)
HE 6 17 26
IHC 9 14 39
RT–PCR 15 8 65
Table 6 Detection of axillary sentinel lymph node (SLN) metastasis by
various procedures
Metastasis
Number (%)
SLN non-SLN
Detection procedure n¼45 n¼304 P-value
H&E 6 (13.3) 10 (3.2) o0.001
IHC 10 (22.2) 11 (3.5) o0.0001
RT–PCR 11 (24.4) 36 (11.8) o0.05
H&E¼haematoxylin and eosin; IHC¼immunohistochemistry.
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RT–PCR and immunohistochemistry.
The detection of metastases would be more reliable if
quantitative evaluation were employed in the RT–PCR assay,
because faint signals from normal lymphocytes could be distin-
guished from cancer-related signals by the signal intensity
difference. In order to eliminate false positives resulting from
amplification of the illegitimate CK19 expression from lymph
nodes, we attempted to determine the cutoff value that could
distinguish the cancer-specific expression from illegitimate ex-
pression, and selected a more sensitive and reliable one. Although
the cutoff value that we selected was set at a relatively high value,
our quantitative RT–PCR assay was sensitive enough. It is
speculated that the higher CK19 mRNA levels might reflect a
higher tumour burden in the lymph node. However, it is still
unclear for just how few a number of cancer cells it would be
possible to only detect by RT–PCR assay and still be capable of
growing to form clinically detectable metastatic foci.
A sentinel lymph node is defined as the first lymph node
that receives the lymphatic drainage from the primary tumour to
reach the lymph node. We previously reported the usefulness
of sentinel lymph node biopsy using a dual mapping procedure
combining dye-guided and gamma probe-guided methods, and
demonstrated a high diagnostic accuracy of 95%; a sensitivity of
89%, and a specificity of 100% were achieved in the diagnosis
of axillary metastasis (Tsugawa et al, 2000). Giuliano et al
(1994) reported that sentinel lymph nodes were significantly
more likely to contain metastases than nonsentinel lymph
nodes removed during axillary lymph node dissection. Our
study also demonstrated that sentinel lymph nodes contain
metastases more frequently than nonsentinel lymph nodes
irrespective of metastasis detection procedure. These results
may partly depend upon the different sampling procedures
between sentinel and nonsentinel nodes by H&E or immunohis-
tochemistry, as Figure 1 was described. However, the whole half
volume of the entire lymph nodes either in sentinel or nonsentinel
nodes was examined by RT–PCR assay. Therefore, in the RT–PCR
assay, we could justifiably compare the metastatic rate in sentinel
node with nonsentinel node regardless of the extent of the
sampling procedure. We could confirm the reliability of the
sentinel lymph node concept using the quantitative RT–PCR
technique to detect metastasic cancer cells. RT–PCR of only
sentinel nodes based on the sentinel node hypothesis would save
time and reduce cost to detect axillary lymph node metastasis in
breast cancer patient.
It remains controversial whether micrometastatic disease in
pathology-negative, but RT–PCR-positive, lymph nodes is
clinically significant. Several studies report clinical relevance of
RT–PCR for the detection of axillary lymph node metastasis in
breast cancer (Masuda et al, 2000; Sakaguchi et al, 2003). However,
these studies had used conventional RT–PCR assay and was
relatively subjective. Since the results obtained from conventional
RT–PCR assay may change under various experimental condi-
tions, it is difficult to compare accurately the amount of metastatic
cancer cell in lymph node with the patient prognosis. Godfrey et al
(2001) reported that quantitative RT–PCR in oesophageal cancer
offers significant benefits over standard RT–PCR and identifies
node-negative patients at high risk for recurrence. The application
of quantitative RT–PCR assay in lymph node of breast cancer
patients might disclose the prognostic significance of micrometa-
static disease. In the present study, we could not assess the
prognostic value of micrometastatic disease or the amount of
metastatic cells using quantitative RT–PCR assay, because of the
small sample size and the short observation time. However, in the
future, the clinical implication of quantitative RT–PCR findings
will be derived from the clinical follow-up of these patients or a
more large-scale study.
Although it is well established that axillary lymph node status is
the most powerful predictor of patient outcome in breast cancer,
no study had focused on the quantity of cancer cells present in the
metastatic lymph nodes, because it was considered up to now that
no method could evaluate objectively the quantity of metastatic
cancer cells. On the other hand, it is cumbersome to quantify
cancer cells in all resected lymph node specimens. As described
above, if the sentinel lymph nodes can be used to predict axillary
lymph node status, the quantity of cancer cells in axillary lymph
node specimens can be replaced by focusing on the quantification
in the sentinel lymph node specimens. Within this framework, the
application of our method to sentinel lymph node biopsy may be a
useful prognostic factor. It will be necessary to ascertain whether
the quantitative value of cancer cells in the sentinel lymph nodes
really does exhibit some relationship to the prognosis and the need
for additional, adjuvant therapy by following up further with these
patients.
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